§ Mr. AtkinsonTo ask the Secretary of State for Health when he expects to make a decision on the provision of manufacturers' site identification on labels of pharmaceutical products; and if he will make a statement.
§ Mr. MellorWe cannot yet say. The proposal to require site declaration was particularly controversial and account must be taken of comments received in consultation before decisions are reached on MLX 167 proposals as a whole.